Datapoint: Amgen to Acquire Horizon Therapeutics

Amgen on Dec. 12 said it reached an agreement to acquire Horizon Therapeutics in a $27.8 billion deal, winning a bidding war that included Johnson & Johnson and Sanofi. Horizon focuses on anti-inflammatory and autoimmune drugs — its lead products include the eye drug Tepezza, anti-grout drug Krystexxa and immunosuppressant Uplinza. The drugmaker brought in $3.2 billion in global sales for 2021. Its most recent FDA approval was a July 2022 label expansion for Krystexxa in uncontrolled gout. For the treatment of gouty arthritis, Krystexxa currently holds covered or better status for 56% of all insured lives under the pharmacy benefit, and 82% under the medical benefit.

SOURCE: MMIT Analytics, as of 12/14/22, and Evaluate Pharma

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 8

Datapoint: CMS Announces Special Enrollment Period for PHE Medicaid Coverage Losses

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 7

Datapoint: Gilead Scores Broader Breast Cancer Nod for Trodelvy

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 6

Datapoint: New Mexico Cancels Medicaid RFP

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today